Abstract
After decades of arduous work, considerable progress has been made in developing a new generation of treatments that may ease symptoms of Alzheimer's disease and might even stop its progression. Several compounds are in mid- and late-stage clinical trials, and the first new drugs could be marketed in a few years. The drugs could be used to keep the disease in check, giving patients the prospect of living relatively normal lives.
| Original language | English |
|---|---|
| Pages (from-to) | 185-189 |
| Number of pages | 5 |
| Journal | Drug Discovery Today: Therapeutic Strategies |
| Volume | 5 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2008 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Passive immunotherapies for Alzheimer's disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver